ArticleJournal of contemporary brachytherapy2025
Precision brachytherapy for bulky cervical tumors: Clinical implementation of a 3D-printed template and curved needle system.
Article in Journal of contemporary brachytherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- The value of pre-brachytherapy MRI in aiding applicator selection for cervical cancer procedures.Journal of contemporary brachytherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Locally advanced cervical cancer (LACC) in bulky tumors and parametrial invasion poses substantial challenges for effective brachytherapy, often resulting in sub-optimal target coverage and increased risk for adjacent organs. This study evaluated the clinical feasibility, dosimetric performance, and early outcomes of a novel high-dose-rate brachytherapy strategy using patient-specific 3D-printed templates and curved flexible needles in LACC. Material and methods: We retrospectively analyzed 20 patients with stage IIIB-IVB cervical cancer treated between July 2023 and August 2024. All patients received pelvic intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy, followed by brachytherapy Results: The mean high-risk clinical target volume (HR-CTV) was V Conclusions: The integration of 3D-printed templates and curved flexible needles enables precise and individualized brachytherapy for bulky and parametrial invasive cervical cancer, achieving high target conformity and effective organ sparing. This approach demonstrates promising early efficacy and safety, supporting its potent advanced solution for complex LACC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.